Printer Friendly

R.P. SCHERER OPENS NEW FACILITY

 TROY, Mich., June 14 /PRNewswire/ -- R.P. Scherer Corporation (NYSE: SHR) announced today that its subsidiary, Scherer DDS Limited, had officially opened the new development facility for its PULSINCAP technology in Clydebank, Scotland. The building represents a U.S.$4.0 million capital investment in new laboratories and pilot plant for a novel drug delivery system which could revolutionize the treatment of many disease conditions. The official opening ceremony was undertaken by Mr. Allan Stewart, M.P., Minister for Industry and Local Government at the Scottish Office, who has supported R.P. Scherer's operation with investment grants.
 The PULSINCAP dosage form is being developed to control the timing of delivery of a medicine and its site of delivery in the body. Scientists now recognize that certain diseases have rhythmic patterns and are best treated by drug treatment which reflects such rhythms. For example, very common conditions such as coronary heart disease, asthma and arthritis all have increased symptoms during the night or in the early morning. Traditional drug treatment has not fully addressed the problem of obtaining maximum drug effect at a time when the patient may be asleep. The PULSINCAP system is expected to be the first system designed to be taken by a patient before going to bed and to provide maximum drug coverage many hours later when the patient is most vulnerable in the early morning.
 Mr. Aleksandar Erdeljan, President of R.P. Scherer Corporation, commented at the opening ceremony, "We have, with this new facility, reached a significant milestone with our PULSINCAP technology as we are now in a position to manufacture clinical trial batches of products for the many companies with whom we are developing PULSINCAP products".
 R.P. Scherer Corporation, an international developer and manufacturer of drug delivery systems, is the world's largest producer of soft gelatin capsules ("softgels"). The company is currently developing and commercializing advanced drug delivery systems, including SCHERERSOL(R), ZYDIS(R) and PULSINCAP(TM) technologies. The company's proprietary drug delivery systems improve the efficacy of drugs by regulating the dosage, rate of absorption and place of release. The company operates a global network of 15 facilities in 11 countries. ZYDIS, PULSINCAP and SCHERERSOL are registered trademarks of R.P. Scherer Corporation.
 -0- 6/14/93
 /CONTACT: Nicole Williams, Executive VP & CFO, R.P. Scherer, 313-649-0900/
 (SHR)


CO: R.P. Scherer Corporation ST: Michigan IN: MTC SU:

ML -- DE025 -- 1676 06/14/93 13:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 14, 1993
Words:405
Previous Article:STC SUBMARINE SYSTEMS WINS US$124 MILLION CONTRACT TO SUPPLY FIRST UNDERSEA OPTICALLY AMPLIFIED LINK IN EUROPE
Next Article:OLD DETROIT ALE LINE ADDS PACKAGES
Topics:


Related Articles
SCHERER APPOINTS JOSEPH A. CLARK III PRESIDENT OF PHARMAPHIL
SCHERER ANNOUNCES LAUNCH OF ANOTHER PRODUCT UTILIZING ITS ZYDIS TECHNOLOGY
SCHERER OPENS NEW ZYDIS MANUFACTURING FACILITY
SCHERER ANNOUNCES ISSUANCE OF $100 MILLION IN SENIOR NOTES
R.P. SCHERER ANNOUNCES CAPACITY EXPANSION
R.P. SCHERER APPOINTS THOMAS J. STUART AS SENIOR VICE PRESIDENT CORPORATE PLANNING AND DEVELOPMENT
SCHERER APPOINTS GEORGE FOTIADES GROUP PRESIDENT
SCHERER APPOINTS MICHAEL CASHMAN GENERAL MANAGER OF SCHERER NORTH AMERICA
Scherer Announces Opening of Softgel Cytotoxics Facility
Scherer And Glaxo Sign Agreements

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters